Physician profile
Deon Wolpowitz
NPI 1396753307
$5,177.97
in general payments reported to CMS, 2019-2025
25 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $397 · 2021: $863 · 2022: $835 · 2023: $901 · 2024: $973 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.09 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,723.38 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Leo Pharma INC. | $542.56 | 2019-2025 | Anzupgo |
| Lilly USA, LLC | $417.89 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $305.87 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $266.47 | 2022-2025 | Sotyktu |
| Incyte Corporation | $206.49 | 2022-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $200.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $187.05 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $172.22 | 2021-2025 | Nemluvio, Aklief |
| Pfizer INC. | $161.78 | 2019-2025 | |
| Ucb, INC. | $155.35 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $146.02 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $141.93 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $141.53 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $82.15 | 2023-2024 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $66.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.09 | 2022-2023 | Spevigo |
| Vyne Pharmaceuticals INC. | $49.25 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $34.07 | 2022 | |
| Botanix Sb INC | $26.28 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.95 | 2021 | |
| Biofrontera INC. | $18.52 | 2019 | |
| Strata Skin Sciences, INC. | $17.13 | 2025 | Xtrac |
| Mission Pharmacal Company | $15.45 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.42 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deon Wolpowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.